160 Health International Ltd (2656) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of 160 Health International Ltd HK$0.71, price HK$4.44, upside -84.0%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch 160 Health International Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
12‑month range HK$4.44 – HK$151.00 · fair‑value band HK$0.4700 – HK$0.8900 · the HK$4.44 price screens above the HK$0.7100 fair value. As of Sep 24, 2026.
Follow 160 Health International in your weekly email
Every Wednesday you see whether 160 Health International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
160 Health International Limited wholesales and retails pharmaceutical and healthcare products in China.
Show more
160 Health International Limited wholesales and retails pharmaceutical and healthcare products in China. Thedevelops Healthcare 160 Platform, an online healthcare and wellness service platform which provides digital healthcare and wellness solutions, including online marketing solutions, digital hospital solutions, and online healthcare services to business customers, medical and healthcare institutions, medical professionals, individual users, and third-party merchants. 160 Health International Limited was founded in 2005 and is headquartered in Shenzhen, the People's Republic of China.
Stock analysis
160 Health International Ltd (2656) currently trades at HK$4.44, while our model-based Fair Value estimate is HK$0.7100, implying the stock looks roughly 525.4% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 90/100, which puts the evidence level at low.
Scenario range: HK$0.4700 (bear) to HK$0.8900 (bull), the price of HK$4.44 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
160 Health International Ltd reported revenue of 652M CNY in FY2025 versus 526M CNY in FY2022, a compound +7.4%/yr. Reported net income was −73.0M CNY in FY2025.
Key figures
Market cap HK$3.3B (≈ $422M) · P/S ratio 5.07 · EPS (TTM) HK$−0.0100 · Net margin −11.2% · Return on equity −102% · Return on assets (EBIT) −32.5% · Operating margin −15.4% · Revenue (TTM) HK$652M.
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −84%, 2656 screens richer than that median.
Fair Value models
Bear HK$0.4700Fair Value HK$0.7100Bull HK$0.8900
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+5.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15.1% (2022) → −9.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare 160 Health International Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−86% · Bottom 25%
Profitability
Return on assets−9% · Bottom 25%
Net margin (TTM)−11% · Bottom 25%
Operating margin (TTM)−15% · Bottom 25%
Growth and dividend
Revenue growth4% · Above median
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/B1.76× · Priciest 25%
P/S (TTM)0.65× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 32
FUTURE (revenue growth)21· sector 17
PAST (return on equity)0· sector 27
HEALTH (low debt)99· sector 96
DIVIDEND (yield)0· sector 59
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "160 Health International Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2656
Frequently asked questions
Is 160 Health International Ltd (2656) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$0.7100 versus a price of HK$4.44, about −84% upside (overvalued).
What is the fair value of 2656?
Our model-based fair value for 160 Health International Ltd is HK$0.7100 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$4.44.
What is the quality score of 2656?
160 Health International Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for 160 Health International Ltd (2656)?
Our model-based price target is the fair value of HK$0.7100 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario HK$0.4700, optimistic scenario HK$0.8900. It is a calculation from audited fundamentals, not an analyst target.
What is the 160 Health International Ltd stock forecast for 2026?
Our models put fair value at HK$0.7100, about −84% upside versus a price of HK$4.44 (overvalued). Cautious scenario HK$0.4700, optimistic scenario HK$0.8900. The calculation is refreshed regularly with new filings.
What is the revenue of 160 Health International Ltd (2656)?
160 Health International Ltd reported trailing-twelve-month revenue of about HK$652M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of 160 Health International Ltd (2656)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For 160 Health International Ltd it is HK$0.7100 per share (as of Sep 24, 2026), against a price of HK$4.44. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is 160 Health International Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 2656 trades above its calculated fair value: price HK$4.44, fair value HK$0.7100, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2656?
No. The price is what the market pays today (HK$4.44); the fair value is what the company's own numbers justify (HK$0.7100). For 160 Health International Ltd the two are HK$3.73 per share apart. That gap is exactly why we show both numbers side by side.
How much is 160 Health International Ltd worth?
The market values 160 Health International Ltd at about HK$3.3B (market capitalisation, as of Sep 24, 2026). Per share that is HK$4.44; our models calculate a fair value of HK$0.7100 per share.
What do the bullish and bearish scenarios say about 2656?
Our models span a range for 160 Health International Ltd: cautious scenario HK$0.4700, base HK$0.7100, optimistic HK$0.8900 per share (as of Sep 24, 2026, price HK$4.44). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of 160 Health International Ltd (2656)?
Balance-sheet figures for 160 Health International Ltd (as of Sep 24, 2026): return on equity −102.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
Which stocks are comparable to 160 Health International Ltd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is 160 Health International Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price HK$4.44, calculated fair value HK$0.7100 (−84%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2656 calculated?
We run 160 Health International Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.7100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. 160 Health International Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of 160 Health International Ltd (2656)?
The closing price on Sep 23, 2026 was HK$4.44. Our model-based fair value is HK$0.7100, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with 160 Health International Ltd right now?
The price sits above even our optimistic bull case (HK$0.8900). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.4700 to HK$0.8900) leaves room in how you read the outcome.
Key figures of 160 Health International Ltd
How large is the market capitalisation of 160 Health International Ltd (2656)?
The market capitalisation of 160 Health International Ltd is HK$3.3B (≈ $422M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of 160 Health International Ltd (2656)?
The price-to-sales ratio of 160 Health International Ltd is 5.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of 160 Health International Ltd (2656)?
Earnings per share at 160 Health International Ltd are HK$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of 160 Health International Ltd (2656)?
The net margin of 160 Health International Ltd is −11.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of 160 Health International Ltd (2656)?
The return on equity (ROE) of 160 Health International Ltd is −102% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of 160 Health International Ltd (2656)?
On an EBIT basis the return on assets of 160 Health International Ltd is −32.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of 160 Health International Ltd (2656)?
The operating margin of 160 Health International Ltd is −15.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at 160 Health International Ltd (2656)?
Revenue at 160 Health International Ltd is growing +4.1% versus a year earlier (3y avg +7.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does 160 Health International Ltd (2656) generate?
The free cash flow of 160 Health International Ltd is −HK$119M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does 160 Health International Ltd (2656) carry?
The net debt of 160 Health International Ltd is HK$32.4M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch 160 Health International Ltd in the live analysis
One click puts 160 Health International Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
